Key result
Trimetazidine added to conventional therapy significantly reduced Tpeak-Tend dispersion from 63.53 to 42.35 ms (P=0.006) in patients with chronic heart failure, particularly in ischemic patients.
Why the study?
Does trimetazidine improve ventricular repolarization dispersion in patients with chronic heart failure?
RCT (n=30)
Does trimetazidine improve ventricular repolarization dispersion in patients with chronic heart failure?
p-value: p=0.006
Trimetazidine reduces Tpeak-Tend dispersion in patients with postischemic chronic heart failure, suggesting a potential antiarrhythmic mechanism.
No takes yet. Share an insight, caveat, or question.
May reduce arrhythmic substrate in ischemic HF; extends metabolic modulation effects on repolarization in chronic HF.
Cera et al. (2010) conducted an RCT in Chronic heart failure (n=30). Trimetazidine (TMZ) vs. Conventional therapy alone was evaluated on Tpeak-Tend dispersion (Tpeak-Tend-d) (p=0.006). Trimetazidine added to conventional therapy significantly reduced Tpeak-Tend dispersion from 63.53 to 42.35 ms (P=0.006) in patients with chronic heart failure, particularly in ischemic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: